DIVI’S LABORATORIES LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹3740
- Today's High:
- ₹3848.6001
- Open Price:
- ₹3740
- 52W Low:
- ₹2708.1335
- 52W High:
- ₹3917.3695
- Prev. Close:
- ₹3733.75
- Volume:
- 15761
Company Statistics
- Market Cap.:
- ₹966.05 billion
- Book Value:
- 480.927
- Revenue TTM:
- ₹72.91 billion
- Operating Margin TTM:
- 22.95%
- Gross Profit TTM:
- ₹44.96 billion
- Profit Margin:
- 20.26%
- Return on Assets TTM:
- 9.11%
- Return on Equity TTM:
- 14.89%
Company Profile
DIVI’S LABORATORIES LTD. had its IPO on under the ticker symbol DIVISLAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. DIVI’S LABORATORIES LTD. has a staff strength of 8,433 employees.
Stock update
Shares of DIVI’S LABORATORIES LTD. opened at ₹3740 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹3740 - ₹3848.6, and closed at ₹3785.1.
This is a +1.38% increase from the previous day's closing price.
A total volume of 15,761 shares were traded at the close of the day’s session.
In the last one week, shares of DIVI’S LABORATORIES LTD. have increased by +4.18%.
DIVI’S LABORATORIES LTD.'s Key Ratios
DIVI’S LABORATORIES LTD. has a market cap of ₹966.05 billion, indicating a price to book ratio of 7.1685 and a price to sales ratio of 9.7079.
In the last 12-months DIVI’S LABORATORIES LTD.’s revenue was ₹72.91 billion with a gross profit of ₹44.96 billion and an EBITDA of ₹20.19 billion. The EBITDA ratio measures DIVI’S LABORATORIES LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, DIVI’S LABORATORIES LTD.’s operating margin was 22.95% while its return on assets stood at 9.11% with a return of equity of 14.89%.
In Q2, DIVI’S LABORATORIES LTD.’s quarterly earnings growth was a negative -49.3% while revenue growth was a negative 21.1%.
DIVI’S LABORATORIES LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 52.7593
- PEG
Its diluted EPS in the last 12-months stands at ₹68.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into DIVI’S LABORATORIES LTD.’s profitability.
DIVI’S LABORATORIES LTD. stock is trading at a EV to sales ratio of 9.3278 and a EV to EBITDA ratio of 21.3951. Its price to sales ratio in the trailing 12-months stood at 9.7079.
DIVI’S LABORATORIES LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0.81% and a payout ratio of 53.91%.
Balance sheet and cash flow metrics
- Total Assets
- ₹144.39 billion
- Total Liabilities
- ₹11.01 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 53.91%
DIVI’S LABORATORIES LTD. ended 2024 with ₹144.39 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹144.39 billion while shareholder equity stood at ₹127.67 billion.
DIVI’S LABORATORIES LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹11.01 billion in other current liabilities, in common stock, ₹109.58 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹1.70 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
DIVI’S LABORATORIES LTD.’s total current assets stands at ₹93.12 billion while long-term investments were ₹0 and short-term investments were ₹40.49 billion. Its net receivables were ₹17.93 billion compared to accounts payable of ₹7.63 billion and inventory worth ₹30.00 billion.
In 2024, DIVI’S LABORATORIES LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, DIVI’S LABORATORIES LTD. paid ₹0.54 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹3785.1
- 52-Week High
- ₹3917.3695
- 52-Week Low
- ₹2708.1335
- Analyst Target Price
- ₹
DIVI’S LABORATORIES LTD. stock is currently trading at ₹3785.1 per share. It touched a 52-week high of ₹3917.3695 and a 52-week low of ₹3917.3695. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹3668.91 and 200-day moving average was ₹3314.8 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5235.8% of the company’s stock are held by insiders while 2776.3% are held by institutions.
Frequently Asked Questions About DIVI’S LABORATORIES LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Divi’s Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, North America, Asia, Europe, and internationally. It also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi’s Research Center and changed its name to Divi’s Laboratories Limited in 1994. The company was incorporated in 1990 and is headquartered in Hyderabad, India.